Management of Post-Stroke Cognitive Impairment

Introduction to Guidelines

The American Heart Association/American Stroke Association recommends that no pharmaceutical agent be used as first-line treatment for post-stroke cognitive impairment, due to lack of consistent evidence of pharmacological efficacy, and instead prioritizes non-pharmacological interventions as first-line treatment 1

The American Heart Association/American Stroke Association guidelines from 2023 state that no pharmaceutical agent has demonstrated consistent positive effects on post-stroke cognition, despite some small studies showing benefits, and therefore non-pharmacological interventions are recommended as first-line treatment 1
Non-pharmacological interventions, such as clinician-directed cognitive rehabilitation, regular physical exercise programs, and enriched environments with cognitive activities, are recommended as first-line treatment for post-stroke cognitive impairment 2
Cholinesterase inhibitors (donepezil, galantamine, rivastigmine) have consistent evidence for improving cognition only in patients with dementia, not specifically for post-stroke cognitive impairment 2

For a patient with post-stroke cognitive impairment, the recommended approach includes excluding reversible causes, such as thyroid dysfunction, vitamin B12 deficiency, and infection, and revising medications, particularly anticholinergic and sedative medications 3
Screening for post-stroke depression, which affects 25-75% of stroke survivors and can mimic or exacerbate cognitive symptoms, using a validated screening tool, is recommended 3
Treating depression, if present, with selective serotonin reuptake inhibitors (SSRIs) as first-line treatment, can greatly improve rehabilitation outcomes, with a level of evidence A 3
Initiating cognitive rehabilitation, including training to develop compensatory strategies, for patients with mild memory deficits, with a level of evidence B 3
Prescribing a regular physical exercise program to improve cognitive function 2
Aggressively managing vascular risk factors, such as blood pressure, diabetes, dyslipidemia, and atrial fibrillation, to prevent stroke recurrence and further cognitive decline 4

The American Heart Association/American Stroke Association guidelines advise against using donepezil as first-line treatment for post-stroke cognitive impairment in the absence of documented dementia 1, 2
Non-pharmacological interventions, which have more robust evidence, should not be neglected 2
Comorbid depression, which can resolve cognitive symptoms once treated, should not be ignored 3
Anticholinergic medications, which can worsen cognition, should be avoided 2